TR200100901T2 - Kateter-bazında revaskülarizasyonu önleme veya geciktirme yöntemi - Google Patents

Kateter-bazında revaskülarizasyonu önleme veya geciktirme yöntemi

Info

Publication number
TR200100901T2
TR200100901T2 TR2001/00901T TR200100901T TR200100901T2 TR 200100901 T2 TR200100901 T2 TR 200100901T2 TR 2001/00901 T TR2001/00901 T TR 2001/00901T TR 200100901 T TR200100901 T TR 200100901T TR 200100901 T2 TR200100901 T2 TR 200100901T2
Authority
TR
Turkey
Prior art keywords
catheter
revascularization
delaying
preventing
based method
Prior art date
Application number
TR2001/00901T
Other languages
English (en)
Inventor
Michael Black Donald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200100901(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200100901T2 publication Critical patent/TR200100901T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

Koroner arter hastalarinda kolesterolun siddetle düsürülmesi kateter-bazinda revaskülarizasyon ihtiyacini önler veya geciktirir.
TR2001/00901T 1998-09-30 1999-07-08 Kateter-bazında revaskülarizasyonu önleme veya geciktirme yöntemi TR200100901T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30

Publications (1)

Publication Number Publication Date
TR200100901T2 true TR200100901T2 (tr) 2001-08-21

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00901T TR200100901T2 (tr) 1998-09-30 1999-07-08 Kateter-bazında revaskülarizasyonu önleme veya geciktirme yöntemi

Country Status (34)

Country Link
US (1) US20080119561A1 (tr)
EP (1) EP1117392B1 (tr)
JP (1) JP2002525321A (tr)
KR (1) KR20010079955A (tr)
CN (1) CN1197565C (tr)
AP (1) AP1708A (tr)
AT (1) ATE260100T1 (tr)
AU (1) AU768474B2 (tr)
BG (1) BG105471A (tr)
BR (1) BR9914098A (tr)
CA (1) CA2343299C (tr)
CZ (1) CZ20011035A3 (tr)
DE (1) DE69915084T2 (tr)
DK (1) DK1117392T3 (tr)
EA (1) EA007427B1 (tr)
EE (1) EE200100199A (tr)
ES (1) ES2214872T3 (tr)
HR (1) HRP20010236A2 (tr)
HU (1) HUP0103648A3 (tr)
ID (1) ID30255A (tr)
IL (2) IL141953A0 (tr)
IS (1) IS5889A (tr)
NO (1) NO20011615L (tr)
NZ (1) NZ510500A (tr)
OA (1) OA11787A (tr)
PL (1) PL346980A1 (tr)
PT (1) PT1117392E (tr)
SI (1) SI1117392T1 (tr)
SK (1) SK4122001A3 (tr)
TR (1) TR200100901T2 (tr)
UA (1) UA73292C2 (tr)
WO (1) WO2000018395A1 (tr)
YU (1) YU23901A (tr)
ZA (1) ZA200102230B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203326A3 (en) 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
AU2001264731A1 (en) * 2000-07-14 2002-01-30 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5807388A (en) * 1994-05-25 1998-09-15 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
AU3667297A (en) * 1996-07-09 1998-02-02 Merck & Co., Inc. Therapy for combined hyperlipidemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
UA73292C2 (en) 2005-07-15
CZ20011035A3 (cs) 2001-10-17
ES2214872T3 (es) 2004-09-16
CA2343299A1 (en) 2000-04-06
AU4975099A (en) 2000-04-17
ID30255A (id) 2001-11-15
BG105471A (bg) 2001-12-31
CN1342072A (zh) 2002-03-27
AP2001002112A0 (en) 2001-06-30
NO20011615L (no) 2001-04-24
EP1117392B1 (en) 2004-02-25
PL346980A1 (en) 2002-03-11
SK4122001A3 (en) 2002-06-04
BR9914098A (pt) 2001-07-31
OA11787A (en) 2005-07-26
YU23901A (sh) 2003-07-07
SI1117392T1 (en) 2004-06-30
EP1117392A1 (en) 2001-07-25
CA2343299C (en) 2008-04-01
IS5889A (is) 2001-03-14
AP1708A (en) 2007-01-10
EE200100199A (et) 2002-06-17
AU768474B2 (en) 2003-12-11
DE69915084T2 (de) 2004-07-22
DK1117392T3 (da) 2004-06-14
DE69915084D1 (de) 2004-04-01
HUP0103648A2 (hu) 2003-08-28
PT1117392E (pt) 2004-07-30
IL141953A (en) 2006-07-05
HUP0103648A3 (en) 2003-10-28
ATE260100T1 (de) 2004-03-15
JP2002525321A (ja) 2002-08-13
IL141953A0 (en) 2002-03-10
WO2000018395A1 (en) 2000-04-06
NO20011615D0 (no) 2001-03-29
CN1197565C (zh) 2005-04-20
KR20010079955A (ko) 2001-08-22
US20080119561A1 (en) 2008-05-22
EA200100370A1 (ru) 2001-10-22
NZ510500A (en) 2003-10-31
ZA200102230B (en) 2002-06-18
EA007427B1 (ru) 2006-10-27
HRP20010236A2 (en) 2002-04-30
HK1042436A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
AU7913800A (en) Catheter for carrying out the combined examination of the left ventricle and of the right and left coronary arteries
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
PT1002795E (pt) Pirimidinas inibidoras da replicacao do hiv
EP1416993A4 (en) CATHETER FOR REMOVING EMBOLI FROM SAPHENA PROSTHESES AND NATIVE CORONAR ATERES
PT97660A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina
IS2321B (is) Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum
BR9811099A (pt) Inibidores de urocinase
TR199701669A1 (tr) Deri preparasyonu için bilesimler.
YU23901A (sh) Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
NO20011583D0 (no) 2-methyl-thieno-benzodiazepine formulering
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
WO2000037062A3 (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
FI973184A0 (fi) Kombinaatioterapia HIV-infektiota varten käyttäen HIV-proteaasi-inhibiittoria indinavir ja käänteistranskriptaasi-inhibiittoria 3TC, mahdollisesti yhdessä AZT:n, DDI:n tai DDC:n kanssa
NL193531B (nl) Ontruimingsstelsel voor een buitengaats werkeiland of dergelijke.
MY140504A (en) Statin-mmp inhibitor combinations
IT1318420B1 (it) Stent perfezionato per la dilatazione di vasi sanguigni.
FR2709805B1 (fr) Jeu de supports-cale.
AU2899099A (en) Composition for treatment and prevention of coronary artery disease
IT1316051B1 (it) Procedimento di sintesi di derivati di esaazaisowurtzitano e formapolimorfa alfa di un derivato di esaazaisowurtzitano.
ES1043377Y (es) Guia con dispositivo movil conico con tope distal para stent directo coronario o vascular.
AU2003203575A1 (en) Transmyocardial coronary artery bypass and revascularization
UA34143A (uk) Спосіб ендартеректомії із стегнових і здухвинних артерій та дезоблітератор
IT1293168B1 (it) Struttura da interni di calzature e metodi per attuarla in particolare per snowboarding.